Overview of biopharmaceutical product segments

According to the "National Strategic Emerging Industries Classification Catalog", the biopharmaceutical industry can be divided into three subcategories: chemical drugs, modern traditional Chinese medicine, and biological drugs. , modern Chinese medicine is further divided into traditional Chinese medicine pieces and Chinese patent medicines, and biological medicines are further divided into vaccines, blood products, diagnostic reagents, monoclonal antibodies, etc.

Supply situation of biopharmaceutical segmented products

——The output of chemical preparations has rebounded

After experiencing a sudden drop in output caused by the outbreak of the epidemic in 2020, in 2021 China's output of chemical pharmaceutical preparations has rebounded. Among its five main types of dosage forms, the output of powder injections will increase by 2.5% in 2021, reaching 8.15 billion bottles; the output of injections will decrease by 12.2%, to 11.9 billion bottles; the output of infusions will increase by 4.5%, reaching 14.18 billion bottles; the output of tablets will increase by 1.5%, reaching 2585.3 100 million tablets and capsules increased by 14.2% to 85.52 billion capsules.

——The output of proprietary Chinese medicines is declining year by year

From 2016 to 2022, the national output of proprietary Chinese medicines continued to decline. In 2022, China's cumulative production of proprietary Chinese medicines will reach 2.277 million tons, a decrease of 41,000 tons compared with 2021.

——Vaccine approval and wholesale volume dropped slightly, and blood product procurement volume recovered

With the rapid development of my country’s vaccine market, especially after several major epidemics, from the government to People's awareness of vaccines has improved to varying degrees. Judging from the total number of batches issued, from 2013 to 2019, the number of vaccine batches issued in my country fluctuated. Affected by the COVID-19 epidemic, a total of 650 million vaccines were issued in batches in 2020, a year-on-year increase of 15.89%, the highest growth rate in the past decade. After the impact of the epidemic gradually weakens, China's batch release volume will show a steady fluctuation trend due to restrictions on research and development technology, and will drop slightly to 670 million in 2022.

The 2006 "Work Plan on the Transformation of Plasma Apheresis Stations" clarified that the plasma apheresis stations were established by the health administrative department instead of the blood products enterprise, and the plasma apheresis station established a "one-to-one" supply with the production enterprise. relations, accelerating industry concentration. On July 18, 2007, the State Food and Drug Administration issued the "Notice on the Implementation of the Quarantine Period for Plasma Raw Materials Used in the Production of Blood Products", requiring that starting from July 1, 2008, all plasma raw materials must be quarantined for more than 3 months. Let it stand (known as the "window period" in the industry), and then pass the virus test before it can be put into production. Affected by the policy, the national pulp mining volume dropped by nearly 50% in 2007. From 2007 to 2022, affected by the start of standardized plasma stations and the increase in people's awareness of blood donation, the volume of plasma collection in my country has fluctuated and increased. In 2022, the volume of plasma collection in the blood products industry will exceed 10,000 tons.

Biopharmaceutical product segmentation demand situation: chemical drugs dominate

The market size of my country's chemical drug industry is approximately 883.9 billion yuan, accounting for 47% of the market size of the biopharmaceutical industry The market size of my country's traditional Chinese medicine industry is approximately 467.9 billion yuan, accounting for 25%; the market size of my country's biopharmaceutical industry is approximately 516.2 billion yuan, accounting for approximately 28%. To sum up, chemical drugs currently dominate the biomedical industry market in my country. However, with the rapid development of the biomedical industry, the proportion of biological drugs will gradually increase, and this pattern will be broken.

Biomedicine product segmentation trend: The global development of traditional Chinese medicine products, biopharmaceuticals have become a key growth point

Overall, a large part of my country's biomedicine technology still remains in scientific research. , and has not been effectively converted into productivity. This not only wastes a lot of resources, but also makes our country's production practice unable to keep up with research and development, resulting in a lag in production. From the perspective of product segmentation, chemical drugs still dominate, traditional Chinese medicine products have a global development trend, and biological drugs will become the key growth point of the industry in the future. For more detailed research and analysis on this industry, please see the "China Biopharmaceutical Industry Development Prospects Forecast and Investment Strategic Planning Analysis Report" by the Qianzhan Industry Research Institute.